Clinical trial
Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic…
NCT00314106 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00314106 |
|---|---|
| Title | Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma |
| Official title | Phase II Study Using a Myeloablative Lymphocyte Depleting Regimen of Chemotherapy and Intensive Total Body Irradiation Followed by Infusion of Tumor Reactive Lymphocytes and Reconstitution With CD34+ Stem Cells in Metastatic Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Melanoma |
| Intervention type | Biological, Drug, Radiation |
| Interventions | Melanoma Reactive TIL, Cyclophosphamide, IL-2, Fludarabine, 1200 total body irradiation (TBI) |
| Enrollment | 26 |
| Start date | Apr 1, 2006 |
| Primary completion | Feb 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Apr 12, 2006 |
| Last update posted | Oct 18, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: